A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients-Reference-Cited by-同舟云学术

A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients

Published:2006-04 Issue:4 Volume:44 Page:671-678
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Bain Vincent G.,Kaita Kelly D.,Yoshida Eric M.,Swain Mark G.,Heathcote E. Jenny,Neumann Avidan U.,Fiscella Michele,Yu Ren,Osborn Blaire L.,Cronin Patrick W.,Freimuth William W.,McHutchison John G.,Subramanian G. Mani

Publisher

Elsevier BV

Subject

Hepatology

Reference14 articles.

1. World Health Organization. Hepatitis C [fact sheet no. 164]. Updated October 2000. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed on: October 11, 2005.

2. Pharmacokinetics of peginterferons;Zeuzem;Semin Liver Dis,2003

3. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection;Fried;N Engl J Med,2002

4. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial;Manns;Lancet,2001

5. Current therapy for hepatitis C: pegylated interferon and ribavirin;McHutchison;Clin Liver Dis,2003

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanism of interferon alpha therapy for chronic hepatitis B and potential approaches to improve its therapeutic efficacy;Antiviral Research;2024-01

2. Engineering a New IFN-ApoA-I Fusion Protein with Low Toxicity and Prolonged Action;Molecules;2023-12-08

3. Albumin-based drug designs for pharmacokinetic modulation;Expert Opinion on Drug Metabolism & Toxicology;2020-09-01

4. Structural basis of serum albumin recognition by SL335, an antibody Fab extending the serum half-life of protein therapeutics;Biochemical and Biophysical Research Communications;2020-06

5. Enhancing the antivirus activity of chimeric canine interferon with ricin subunit B by using nanoparticle formulations;RSC Advances;2020